Medical/Pharmaceuticals
Osara Health Expands Into Survivorship Care, Strengthening Cancer Support Beyond Treatment
The expanded Cancer Coach program introduces new survivorship modules building on the latest outcomes showing a 25:1 ROI and ~66% of participants improved physical and mental health. NEW YORK, June 5, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on providing support...
2026-06-05 06:59
3540
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum
2026-06-05 06:00
3838
Global Ergothioneine Market Poised for Accelerated Growth as Scientific Validation and Synthetic Biology Reshape Industry Dynamics
New Frost & Sullivan White Paper Highlights Emerging Opportunities Across Healthy Aging, Functional Nutrition, Personal Care, and Preventive Healthcare SHANGHAI, June 4, 2026 /PRNewswire/ -- Frost & Sullivan's latest white paper, Global Ergothioneine Industry Current Landscape and Development Tre...
2026-06-04 21:35
4294
Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
* WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. * The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate ...
2026-06-04 20:30
3619
PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational
Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development NANJING, China, June 4, 2026 /PRNewswire/ -- PharmaBlock Sciences (Stock Code: 300725.SZ) today announced the commissioning of its first peptide pilot-scale GMP p...
2026-06-04 20:21
3420
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidi...
2026-06-04 18:58
4036
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
* Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan regi...
2026-06-04 18:32
4106
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-06-04 16:35
5461
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
GUANGZHOU, China, June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymp...
2026-06-04 16:19
3930
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
* Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model * Net Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-Year * Total Marketplace (MP) Service Revenue Increased by 24.7% Year-over-Year * Fulfillment E...
2026-06-04 16:00
8122
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a significant step f...
2026-06-04 11:39
3984
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
GLASGOW, Scotland, June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent ...
2026-06-04 06:01
4540
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-06-03 12:00
5379
New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction
Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles. Results revealing no complications and high satisfaction prove the need to adapt surgical techniques for variations in skin ty...
2026-06-03 10:00
4595
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7...
2026-06-03 08:00
5462
Reach Surgical Receives CE Mark Approval for SOUND REACH™ Swift
- The leading innovative plug-and-play ultrasonic shears with integrated transducer designed for open surgery SINGAPORE, June 3, 2026 /PRNewswire/ -- Reach Surgical, the surgical solutions division of Genesis MedTech, has received CE Mark approval for SOUND REACHTM Swift, ultrasonic shears desig...
2026-06-03 07:00
2822
Early Data Show Highly Selective FGFR2 Inhibitor 3HP-2827 Active in Advanced CCA; Chinese Academy of Sciences' Zhou Jian Comments on Potential for Patients With FGFR2 Alterations
CHICAGO, June 2, 2026 /PRNewswire/ -- At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 3H Pharmaceuticals released new clinical data for its wholly owned candidate, 3HP-2827. The ongoing study focuses on patients with advanced cholangiocarcinoma (CCA) and other solid tumor...
2026-06-02 21:30
6015
Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters
The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally CARLSBAD, Calif., June 2, 2026 /PRNewswire/ -- As laboratories increasingly ...
2026-06-02 20:48
3310
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
* Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases * Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diver...
2026-06-02 20:27
5404
SK bioscience Secures First UNICEF Procurement Contract Improving Vaccine Access
* First UNICEF procurement contract strengthens SK bioscience's presence in global public procurement markets * Dual-hemisphere supply programs enhance manufacturing efficiency and operational capabilities * Public procurement programs drive both commercial growth and improved vaccine acces...
2026-06-02 20:00
3802
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
8656
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
6304
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5339
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
5269
